Drug Trial Radar · NCT06906198
Pharmacokinetics of VVN461 Ophthalmic Solution
Last checked: Nov 20, 2026Latest source record: Apr 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Mar 1, 2023
Primary completion
May 10, 2023
Study completion Dec 22, 2023
Sponsor
- Lead sponsor
- VivaVision Biotech, IncIndustry
- Sponsor type
- Industry
- First posted
- Apr 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, double-masked, randomized, vehicle-controlled study conducted in China in adult healthy subjects
Conditions
- Healthy Volunteers
Interventions
VVN461 Ophthalmic Solution 1.0%Drug
VVN461, 1.0%
VVN461 Ophthalmic Solution 0.5%Drug
VVN461, 0.5%
VVN461 Ophthalmic Solution 0.25%Drug
VVN461, 0.25%
VVN461 Ophthalmic Solution PlaceboDrug
Vehicle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety outcomeTime frame: Baseline to Day 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Eye Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.